WebDec 30, 2024 · PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the … The whole-gland treatment with radical prostatectomy is mostly applied in low-risk localized PCa, but it is associated with a low therapeutic index and numerous side effects, such as postoperative incontinence and erectile dysfunction [69]. In recent years, focal therapy, such as vascular-targeted photodynamic … See more Radioligand therapy (RLT) is a treatment by injecting a certain therapeutic dose of radionuclide-labeled ligand into the body; after specifically … See more In recent years, cellular immunotherapy has gained momentum in PCa therapy, and its status has changed from “non-mainstream … See more It marks a great breakthrough in the field of tumor therapy to connect antibodies with cytotoxic drugs via different chemical bonds to obtain the antibody-drug conjugates (ADCs). Compared with the traditional cytotoxic … See more Radical prostatectomy is the preferred treatment of localized PCa. For moderate and high risk localized PCa, extended lymph node … See more
Current Status of PSMA-Targeted Radioligand Therapy in the Era of
WebApr 11, 2024 · Here, we report broad expression of STEAP1 relative to prostate-specific membrane antigen (PSMA) in lethal metastatic prostate cancers and the development of a STEAP1-directed chimeric antigen ... WebJun 23, 2024 · Prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a promising new therapeutic approach to treat metastatic prostate cancer. This tumor-specific treatment is directed against PSMA, which is overexpressed in prostate cancer cells. mouse keyboard sharing between two computers
PARP Inhibitors, PSMA-Directed Therapy Augment the …
WebFeb 11, 2024 · PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer The treatment of patients with metastatic castration-resistant prostate cancer has mostly involved androgen receptor-targeted therapies (ARTTs) and cytotoxic chemotherapy for over a decade. WebApr 14, 2024 · Introduction. Castration-resistant prostate cancer (CRPC), particularly metastatic castration-resistant prostate cancer (mCRPC) is one of the most common cancers in males and affects millions of men worldwide with high morbidity and mortality (Siegel et al., 2024).Treatments for mCRPC are various including chemotherapy, … WebLOCAMETZ ® (kit for the preparation of gallium Ga 68 gozetotide injection), after radiolabeling with gallium-68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy mouse keyboard screen switch